...
now it’s a stroke.
After more than 50 years, a new therapy is now available in South Africa to prevent
strokes caused by atrial fibrillation that offers:
•
35 %
reduced risk of
stroke and systemic embolism
vs. well-controlled warfarin (p
<
0,001)
1,2
•
59 %
reduced risk of
intracranial bleeding
vs. well-controlled warfarin (p
<
0,001)
1,2
•
20 %
reduced risk of
life-threatening bleeding
vs. well-controlled warfarin (p
=
0,03)
1,2
•
Does
not require
regular
INR monitoring
3
•
Does
not interact
with
food
3
A minute ago,
the only thing on Pat’s
mind was gardening...
1,2
S4 Pradaxa® 110 mg. Each capsule contains 110 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 42/8.2/0131
S4 Pradaxa® 150 mg. Each capsule contains 150 mg of dabigatran etexilate base (as mesilate salt). Reg. No. 45/8.2/0162
For full prescribing information refer to the package insert approved by the medicines regulatory authority.
Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd, 407 Pine Ave, Randburg.Tel: +27 (011) 348-2400. Fax: +27 (011) 787-3766. Cpy. Reg. No. 1966/008618/07. BI Ref. No. 341/2012 (Nov 12)
Dabigatran etexilate 110 mg/150 mg
References:
1.
Connolly SJ, Ezekowitz MB,Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Eng J Med 2009;361:1139–1151. 2. Connolly SJ, Ezekowitz MB,Yusuf S et al.
Newly identified events in the RE-LY trial. New Eng J Med 2010;363:1875–1876. 3. Boehringer Ingelheim South African Pradaxa
®
Package insert.
